Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leica's GM To Head Epistem

This article was originally published in Clinica

Executive Summary

Epistem Holdings, the personalized medicine specialist, has appointed David Budd CEO and director. Budd, who officially assumes the position in mid-April, will replace Matthew Walls, who resigned in October last year. The new CEO brings to the Manchester, UK company over 20 years’ experience launching multiple diagnostic products into international markets. He joins from Leica Biosystems (a Danaher company) where he most recently served as general manager of its Amsterdam operations. Prior to Leica, Budd has also held senior commercial roles at Siemens Healthcare Diagnostics, Bayer Diagnostics and Visible Genetics. Epistem’s chairman, Ian Gilham, will continue to serve as interim CEO until Budd joins the company. Epistem’s flagship product is Genedrive, a portable PCR instrument designed for rapid, point of care diagnosis. The initial indications which the firm is targeting are tuberculosis and hepatitis C.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT103137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel